arrow
P

Peter Ostler

Mount Vernon Cancer Centre
H指数:29
被引数:5,274

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Two-year toxicity outcomes from PACE-C: Stereotactic Body Radiotherapy (SBRT) versus moderate hypofractionated radiotherapy (MHRT)

PACE-C研究中的两年毒性结局:立体定向体部放射治疗(SBRT)与中等分割低剂量率放射治疗(MHRT)

2025-10-140
PRE
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial

调强中低分割放射治疗与立体定向体部放射治疗用于前列腺癌的比较(PACE-C):一项随机、开放标签、III期非劣效性试验的早期毒性结果

2025-06-120
PRE
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer
2024-10-171
PRE
Patients’ Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study

新诊断转移性前列腺癌患者对细胞减灭治疗的偏好:IP5-MATTER研究

2024-07-010
OAAI
Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)

根治性前列腺切除术 (RP) 后放疗 (RT) 的时机: radical-rt试验 (NCT00541047) 的长期结果

2024-07-019
OAAI
Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Rucaparib或医生在转移性前列腺癌中的选择

2023-02-23161
OA
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial

根治性前列腺切除术 (radical-rt) 后放疗的时机: 一项随机对照3期试验

LANCET
IF88.5
2020-10-01262
OAAI
Patient Reported Acute Toxicity in PACE-B, an International Phase III Randomised Controlled Trial Comparing Stereotactic Body Radiotherapy to Conventionally Fractionated or Moderately Hypofractionated Radiotherapy (CFMHRT) for Localised Prostate Cancer
2019-09-010
PREAI
Comprehensive genomic profiling of >1000 plasma and tumor tissue samples from metastatic castration-resistant prostate cancer (mCRPC) patients gives insight into targeted treatment strategies
2019-07-013
PRE